|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15491550155115521553155415551556155715581559...15771578» |
- lapatinib / Generic mfg.
Trial initiation date: Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors (clinicaltrials.gov) - May 6, 2014
P2, N=52, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2005 --> Oct 2004
- sapanisertib (CB-228) / Calithera
IO biomarker, Surgery: Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - May 5, 2014
P=N/A, N=40, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Clinical: Monocyte Phenotypic and Functional Differences (clinicaltrials.gov) - May 5, 2014
P=N/A, N=90, Not yet recruiting, Sponsor: Duke University
- onalespib (AT13387) / Otsuka
Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST (clinicaltrials.gov) - May 5, 2014
P2, N=36, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Initiation date: Jan 2005 --> Oct 2004 Trial primary completion date: May 2013 --> May 2014
- Trial primary completion date: A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas (clinicaltrials.gov) - May 5, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: May 2013 --> May 2014 Trial primary completion date: May 2014 --> May 2015
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - May 5, 2014
P2, N=172, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2014 --> May 2015 Trial primary completion date: Apr 2014 --> Jul 2014
- Trial primary completion date: Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients (clinicaltrials.gov) - May 5, 2014
P2, N=104, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2014 --> Jul 2014 Trial primary completion date: Nov 2014 --> Nov 2015
- onalespib (AT13387) / Otsuka
Trial completion date, Combination therapy, Monotherapy, Metastases: A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST (clinicaltrials.gov) - May 5, 2014
P2, N=36, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Trial primary completion date: Nov 2014 --> Nov 2015 Trial completion date: Aug 2013 --> Aug 2014
- adavosertib (AZD1775) / AstraZeneca
Enrollment open, Combination therapy: Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - May 5, 2014
P1/2, N=128, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Aug 2013 --> Aug 2014 Not yet recruiting --> Recruiting
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
New P2 trial, Metastases: LMS02: Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma (clinicaltrials.gov) - May 4, 2014
P2, N=110, Completed, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- |||| Votrient (pazopanib) / Novartis
Enrollment open, Combination therapy: Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma (clinicaltrials.gov) - May 1, 2014
P2, N=80, Recruiting, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting Suspended --> Recruiting
- || sunitinib / Generic mfg.
Trial primary completion date, Stroma: GIST: Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Apr 30, 2014
P4, N=60, Active, not recruiting, Sponsor: Pfizer
Suspended --> Recruiting Trial primary completion date: Apr 2014 --> May 2014
- iC9-GD2-CAR-VZV-CTLs / Baylor College of Medicine
Trial primary completion date, Metastases: VEGAS: iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (clinicaltrials.gov) - Apr 29, 2014
P1, N=26, Recruiting, Sponsor: Baylor College of Medicine
Trial primary completion date: Apr 2014 --> May 2014 Trial primary completion date: Mar 2018 --> Apr 2018
- Hepacid (pegargiminase) / Polaris Pharma
Trial initiation date: Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (clinicaltrials.gov) - Apr 29, 2014
P1, N=47, Recruiting, Sponsor: Polaris Group
Trial primary completion date: Mar 2018 --> Apr 2018 Initiation date: Jul 2014 --> Apr 2014
- iC9-GD2-CAR-VZV-CTLs / Baylor College of Medicine
Trial completion date, Metastases: VEGAS: iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (clinicaltrials.gov) - Apr 29, 2014
P1, N=26, Recruiting, Sponsor: Baylor College of Medicine
Initiation date: Jul 2014 --> Apr 2014 Trial completion date: Dec 2033 --> Apr 2033
- |||| alisertib (MLN8237) / Puma
Enrollment open, Combination therapy: SJATRT: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (clinicaltrials.gov) - Apr 29, 2014
P2, N=160, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial completion date: Dec 2033 --> Apr 2033 Not yet recruiting --> Recruiting
- iC9-GD2-CAR-VZV-CTLs / Baylor College of Medicine
Trial initiation date, Metastases: VEGAS: iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (clinicaltrials.gov) - Apr 29, 2014
P1, N=26, Recruiting, Sponsor: Baylor College of Medicine
Not yet recruiting --> Recruiting Initiation date: Dec 2013 --> Apr 2014
- iC9-GD2-CAR-VZV-CTLs / Baylor College of Medicine
Enrollment open, Metastases: VEGAS: iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (clinicaltrials.gov) - Apr 29, 2014
P1, N=26, Recruiting, Sponsor: Baylor College of Medicine
Initiation date: Dec 2013 --> Apr 2014 Not yet recruiting --> Recruiting
- Hepacid (pegargiminase) / Polaris Pharma
Enrollment open: Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (clinicaltrials.gov) - Apr 29, 2014
P1, N=47, Recruiting, Sponsor: Polaris Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Ixempra (ixabepilone) - Otsuka, R / Pharm
Enrollment closed: Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer (clinicaltrials.gov) - Apr 28, 2014
P2, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | imatinib / Generic mfg.
Enrollment closed, Stroma: Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions (clinicaltrials.gov) - Apr 27, 2014
P2/3, N=48, Active, not recruiting, Sponsor: Amneal Pharmaceuticals, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ID-LV305 / Merck (MSD)
Enrollment open, Metastases: Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 (clinicaltrials.gov) - Apr 24, 2014
P1, N=36, Recruiting, Sponsor: Immune Design
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- letrozole / Generic mfg.
Trial primary completion date, Metastases: Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma (clinicaltrials.gov) - Apr 23, 2014
P2, N=27, Completed, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2013 --> Jan 2013
- | letrozole / Generic mfg.
Enrollment change, Metastases: Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma (clinicaltrials.gov) - Apr 23, 2014
P2, N=27, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jun 2013 --> Jan 2013 N=37 --> 27
- | letrozole / Generic mfg.
Trial completion, Metastases: Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma (clinicaltrials.gov) - Apr 23, 2014
P2, N=27, Completed, Sponsor: Dana-Farber Cancer Institute
N=37 --> 27 Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Metastases: Pazopanib for Metastatic Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Apr 22, 2014
P2, N=19, Recruiting, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- gefitinib / Generic mfg.
Trial initiation date: Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas (clinicaltrials.gov) - Apr 21, 2014
P1/2, N=69, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Aug 2002 --> Jul 2002
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial initiation date: Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma (clinicaltrials.gov) - Apr 21, 2014
P2, N=29, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Initiation date: Aug 2002 --> Jul 2002 Initiation date: May 2007 --> Apr 2007
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change: Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma (clinicaltrials.gov) - Apr 21, 2014
P2, N=29, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Initiation date: May 2007 --> Apr 2007 N=14 --> 29
- || New P3 trial: Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas (clinicaltrials.gov) - Apr 21, 2014
P3, N=400, Recruiting, Sponsor: Fudan University
- | ID-LV305 / Merck (MSD)
New P1 trial, Metastases: Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 (clinicaltrials.gov) - Apr 21, 2014
P1, N=36, Recruiting, Sponsor: Immune Design
- | Enrollment open: Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas (clinicaltrials.gov) - Apr 21, 2014
P3, N=400, Recruiting, Sponsor: Fudan University
N=14 --> 29 Not yet recruiting --> Recruiting
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Apr 21, 2014
P2, N=128, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Terminated --> Completed
- Enrollment open, HEOR, Metastases: Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease (clinicaltrials.gov) - Apr 20, 2014
P=N/A, N=100, Recruiting, Sponsor: Duke University
Terminated --> Completed Not yet recruiting --> Recruiting
- veliparib (ABT-888) / AbbVie
Enrollment change, PARP Biomarker: ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors (clinicaltrials.gov) - Apr 20, 2014
P1, N=31, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=24 --> 31
- ||| Avastin (bevacizumab) / Roche
Enrollment closed: Bevacizumab Beyond Progression (BBP) (clinicaltrials.gov) - Apr 20, 2014
P2, N=68, Active, not recruiting, Sponsor: Duke University
N=24 --> 31 Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / BMS
Trial completion: Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer (clinicaltrials.gov) - Apr 18, 2014
P1, N=28, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Completed
- || evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment closed, Combination therapy, Stroma, Metastases: Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 17, 2014
P1, N=58, Active, not recruiting, Sponsor: Threshold Pharmaceuticals
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Talzenna (talazoparib) / Pfizer
New P1/2 trial, PARP Biomarker: Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies (clinicaltrials.gov) - Apr 15, 2014
P1/2, N=172, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Avastin (bevacizumab) / Roche
Enrollment closed, Surgery: Radiosurgery Plus Bevacizumab in Glioblastoma (clinicaltrials.gov) - Apr 14, 2014
P1/2, N=74, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Trial completion: Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors (clinicaltrials.gov) - Apr 13, 2014
P1, N=94, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||| alisertib (MLN8237) / Puma
New P2 trial, Combination therapy: SJATRT: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (clinicaltrials.gov) - Apr 13, 2014
P2, N=160, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- Votrient (pazopanib) / Novartis, BeiGene
New P2 trial, Metastases: Pazopanib for Metastatic Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Apr 13, 2014
P2, N=19, Recruiting, Sponsor: Seoul National University Hospital
- Enrollment change: Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas (clinicaltrials.gov) - Apr 9, 2014
P2, N=70, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed N=30 --> 70
- Enrollment change: Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors (clinicaltrials.gov) - Apr 8, 2014
P=N/A, N=61, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=30 --> 70 N=210 --> 61
- Trial completion: Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors (clinicaltrials.gov) - Apr 8, 2014
P=N/A, N=61, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=210 --> 61 Active, not recruiting --> Completed
- Enrollment change: Proton or Photon RT for Retroperitoneal Sarcomas (clinicaltrials.gov) - Apr 7, 2014
P1/2, N=80, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed N=40 --> 80
- anti-GD2 CAR-T cell therapy / Bellicum, National Cancer Institute
New P1 trial, IO biomarker: 14-C-0059: A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors (clinicaltrials.gov) - Apr 7, 2014
P1, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
- SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax, Roswell Park Comprehensive Cancer Center
Enrollment closed: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Apr 7, 2014
P1, N=9, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
N=40 --> 80 Recruiting --> Active, not recruiting
- New P2 trial: DOREMY: Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (clinicaltrials.gov) - Apr 6, 2014
P2, N=20, Recruiting, Sponsor: The Netherlands Cancer Institute